Roche wins expedited approval for higher-dose MS drug in India

The Central Drugs Standards Organisation's expert committee has cleared the pathway for Roche to advance its higher-dose formulation of Ocrelizumab without completing traditional Phase 3 trials in India, according to regulatory filings. The decision to waive Phase 3 requirements represents an expedited route to market for the monoclonal antibody therapy, which is used to treat relapsing and primary progressive forms of multiple sclerosis.

The approval grants Roche permission to pursue the 920 mg dose variant, though the company remains obligated to execute Phase 4 post-marketing surveillance studies specifically enrolling Indian patients for the drug's proposed indications. This requirement ensures that real-world safety and efficacy data specific to the Indian population will be collected once the medication becomes available to patients in the country.

The waiver reflects evolving regulatory approaches that balance the need for rapid patient access to advanced therapies with comprehensive safety monitoring. Multiple sclerosis, a chronic autoimmune neurological condition, affects a growing population in India, where access to disease-modifying treatments remains limited in many regions.

Roche's Ocrelizumab targets B cells and has become a cornerstone therapy for moderate-to-severe MS cases globally. The higher-dose formulation may offer improved efficacy or convenience in dosing schedules compared to existing variants, though the company has not disclosed specific clinical advantages associated with the elevated dose.